Cell therapy for Charcot-Marie-Tooth type 1A (CMT1A)
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a new cell therapy called EN001 for people with CMT1A. It aims to see if the treatment is safe and can help with nerve function and muscle weakness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test confirming CMT1A.
- You need to have some muscle weakness, especially when trying to lift your foot (foot drop).
- You must be at least 19 years old.
- If you are able to have children, you must agree to use effective birth control during the study.
- You cannot have diabetes, active tuberculosis, or certain other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called EDK060 for people with Charcot-Marie-Tooth disease type 1A (CMT1A). The study will check if the drug is safe and how the body processes it, with the goal of finding better treatments for this condition.
This trial looks for new markers of Charcot-Marie-Tooth 1A (CMT1A) early in the disease. Researchers hope to find signs that can help diagnose and track the disease better, which could lead to better treatments in the future.
This trial tests whether adding a special vibration device to an intensive rehab program helps improve balance in people with Charcot-Marie-Tooth disease type 1A. If you are between 18 and 65 and have mild to moderate leg weakness, you may be able to join.
This trial tests a gene therapy medicine (ELP-02) given through a spinal tap for children and young adults with a specific genetic form of CMT (CMT4J). It aims to slow or stop the disease from getting worse.
This trial tests a one-time gene therapy (SAR446268) for people with non-congenital myotonic dystrophy type 1. It aims to see if the treatment is safe and can improve muscle symptoms like stiffness and weakness.
This trial tests a personalized medicine designed for a single person with a specific genetic mutation (GARS1) that causes Charcot-Marie-Tooth disease type 2D. The treatment is an antisense oligonucleotide, a custom-made molecule that targets the faulty gene.
Hear when a new Charcot-Marie-Tooth Disease Type 1A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.